We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 04, 2021

Effect of Second-Generation vs Third-Generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III NSCLC

JAMA Oncology

 

Additional Info

JAMA Oncology
Effect of Second-Generation vs Third-Generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non–Small-Cell Lung Cancer: 10-Year Follow-Up of a WJTOG0105 Phase 3 Randomized Clinical Trial
JAMA Oncol 2021 Mar 18;[EPub Ahead of Print], Y Zenke, M Tsuboi, Y Chiba, K Tsujino, M Satouchi, K Sawa, J Shimizu, H Daga, D Fujimoto, M Mori, T Aoki, T Sawa, S Omori, H Saka, Y Iwamoto, M Okuno, T Hirashima, K Kashiwabara, M Tachihara, N Ymamoto, K Nakagawa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading